BR112023024454A2 - Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero - Google Patents
Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômeroInfo
- Publication number
- BR112023024454A2 BR112023024454A2 BR112023024454A BR112023024454A BR112023024454A2 BR 112023024454 A2 BR112023024454 A2 BR 112023024454A2 BR 112023024454 A BR112023024454 A BR 112023024454A BR 112023024454 A BR112023024454 A BR 112023024454A BR 112023024454 A2 BR112023024454 A2 BR 112023024454A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- isomer
- general formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 3
- 239000012453 solvate Substances 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000013038 irreversible inhibitor Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110661394 | 2021-06-15 | ||
| PCT/CN2022/099018 WO2022262784A1 (zh) | 2021-06-15 | 2022-06-15 | Idh突变体抑制剂及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024454A2 true BR112023024454A2 (pt) | 2024-02-06 |
Family
ID=84526875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024454A BR112023024454A2 (pt) | 2021-06-15 | 2022-06-15 | Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240208978A1 (https=) |
| EP (1) | EP4356914A4 (https=) |
| JP (1) | JP2024524933A (https=) |
| KR (1) | KR20240021774A (https=) |
| CN (1) | CN117460512A (https=) |
| AU (1) | AU2022294860A1 (https=) |
| BR (1) | BR112023024454A2 (https=) |
| CA (1) | CA3217608A1 (https=) |
| MX (1) | MX2023013664A (https=) |
| WO (1) | WO2022262784A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026035776A1 (en) * | 2024-08-05 | 2026-02-12 | Frontier Medicines Corporation | Pi3k-alpha binding compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | ２−アミノ置換８−オキソジヒドロプリン誘導体 |
| PL2900675T3 (pl) * | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| JP6387360B2 (ja) * | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| MA46064B1 (fr) * | 2014-09-19 | 2020-04-30 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
| US9624175B2 (en) * | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| ES2764523T3 (es) * | 2015-07-27 | 2020-06-03 | Lilly Co Eli | Compuestos de 7-feniletilamino-4H-pirimido[4,5-D][1,3]oxazin-2-ona y su uso como inhibidores de IDH1 mutantes |
| CN109311863B (zh) | 2016-06-06 | 2021-10-29 | 伊莱利利公司 | 突变型idh1抑制剂 |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| KR102232614B1 (ko) * | 2016-07-21 | 2021-03-29 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용 |
| ES2941631T3 (es) | 2016-12-16 | 2023-05-24 | Lilly Co Eli | Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes |
| CN110872297B (zh) * | 2018-09-04 | 2023-02-14 | 上海再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| WO2020141439A1 (en) * | 2018-12-31 | 2020-07-09 | Integral Biosciences Private Limited | Heterocyclic compounds as mutant idh inhibitors |
-
2022
- 2022-06-15 CA CA3217608A patent/CA3217608A1/en active Pending
- 2022-06-15 EP EP22824259.0A patent/EP4356914A4/en active Pending
- 2022-06-15 KR KR1020237041032A patent/KR20240021774A/ko active Pending
- 2022-06-15 BR BR112023024454A patent/BR112023024454A2/pt unknown
- 2022-06-15 US US18/287,885 patent/US20240208978A1/en active Pending
- 2022-06-15 JP JP2023577688A patent/JP2024524933A/ja active Pending
- 2022-06-15 WO PCT/CN2022/099018 patent/WO2022262784A1/zh not_active Ceased
- 2022-06-15 MX MX2023013664A patent/MX2023013664A/es unknown
- 2022-06-15 AU AU2022294860A patent/AU2022294860A1/en active Pending
- 2022-06-15 CN CN202280040684.0A patent/CN117460512A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240021774A (ko) | 2024-02-19 |
| JP2024524933A (ja) | 2024-07-09 |
| CN117460512A (zh) | 2024-01-26 |
| WO2022262784A1 (zh) | 2022-12-22 |
| US20240208978A1 (en) | 2024-06-27 |
| AU2022294860A1 (en) | 2024-01-25 |
| CA3217608A1 (en) | 2022-12-22 |
| EP4356914A1 (en) | 2024-04-24 |
| MX2023013664A (es) | 2024-01-08 |
| EP4356914A4 (en) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023021383A2 (pt) | Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| MX2021012756A (es) | Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este. | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| MY209754A (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| BR112021016751B8 (pt) | Compostos, composições farmacêuticas e usos dos compostos | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| MX2022006608A (es) | Nuevos inhibidores de aurora cinasa y uso de los mismos. | |
| MX2024005996A (es) | Inhibidor de kif18a. | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| BR112021023765A2 (pt) | Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto | |
| MX2024011317A (es) | Procesos para la preparación de derivados sustituidos de espirooxindol. | |
| ZA202007566B (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| EP4541422A3 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2021011144A (es) | Derivados de las benzodiazepinas como inhibidores del vsr. | |
| BR112023015721A2 (pt) | Derivados tricíclicos úteis como inibidores de parp7 | |
| ZA202400988B (en) | Aak1 inhibitor and use thereof | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| MX2021003662A (es) | Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| CO2022015157A2 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MX2019012967A (es) | Cristal de base libre de derivados benzofurano y metodo de preparacion. |